<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336686</url>
  </required_header>
  <id_info>
    <org_study_id>M102-21122</org_study_id>
    <nct_id>NCT01336686</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout</brief_title>
  <official_title>A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to&#xD;
      placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in&#xD;
      patients with gout.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>Baseline and end of treatment phase (4 wks)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>Arhalofenate 400 mg once daily for 4 weeks</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <other_name>MBX-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arhalofenate</intervention_name>
    <description>Arhalofenate 600 mg once daily for 4 weeks</description>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <other_name>MBX-102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Matching placebo once daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>0.6 mg colchicine daily for flare prophylaxis</description>
    <arm_group_label>Arhalofenate 400 mg</arm_group_label>
    <arm_group_label>Arhalofenate 600 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Read and sign the informed consent after the elements of consent have been fully&#xD;
             explained and all questions have been addressed, prior to any study procedures.&#xD;
&#xD;
          -  Known gout patient (per criteria of the American Rheumatism Association for the&#xD;
             classification of the acute arthritis of primary gout in Appendix 3)&#xD;
&#xD;
               -  the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL&#xD;
&#xD;
               -  if on ULT, the patients must agree to temporarily discontinue their existing ULT&#xD;
                  and the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL after wash-out at Week -1&#xD;
&#xD;
          -  Male or female, 18-75 years of age at Screening Visit&#xD;
&#xD;
          -  All female patients must be surgically sterile or post-menopausal (at least 45 years&#xD;
             of age with no history of menses for at least 2 years; or any age with no history of&#xD;
             menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or have a partner who has&#xD;
             undergone vasectomy or must agree to use two medically accepted methods of&#xD;
             contraception including a barrier method (see the list in Appendix 4) for the entire&#xD;
             duration of the study unless reporting complete sexual abstinence.&#xD;
&#xD;
          -  Female patients must not be pregnant or lactating&#xD;
&#xD;
          -  Male patients with a female partner of child-bearing potential must agree to use&#xD;
             condom or the partner must use a medically acceptable method of contraception for the&#xD;
             entire duration of the study.&#xD;
&#xD;
          -  Patients must have an estimated CrCl ≥ 60 mL/min as calculated by the Cockcroft-Gault&#xD;
             method&#xD;
&#xD;
          -  Serum creatinine value must be ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males&#xD;
&#xD;
          -  Patients must have liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X&#xD;
             ULN for ALP, ≤ 3X ULN for GGT; and ≤ 3X ULN for CK&#xD;
&#xD;
          -  All other clinical laboratory parameters must be within normal limits or considered&#xD;
             not clinically significant for participation in this study&#xD;
&#xD;
          -  Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically&#xD;
             significant for participation in this study&#xD;
&#xD;
          -  Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood&#xD;
             pressure ≤ 90 mm Hg; known hypertensive patients controlled with medication other than&#xD;
             thiazide diuretics (BP reading as above) may be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder,&#xD;
             or organ transplant).&#xD;
&#xD;
          -  Known patient with xanthinuria&#xD;
&#xD;
          -  History of documented or suspected kidney stones&#xD;
&#xD;
          -  Over producers of uric acid as evidenced by 24-hour urinary uric acid &gt; 800 mg (on&#xD;
             normal unrestricted diet)&#xD;
&#xD;
          -  Known infection with the human immunodeficiency virus (HIV) or history of viral&#xD;
             hepatitis type B or C&#xD;
&#xD;
          -  History of illicit drug or alcohol abuse within last 1 year&#xD;
&#xD;
          -  History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer&#xD;
             disease (unless known H. pylori infection treated successfully without recurrence), or&#xD;
             nephrotic syndrome within last 3 years&#xD;
&#xD;
          -  All patients must not have had a stroke, TIA, acute myocardial infarction, congestive&#xD;
             heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure&#xD;
             (including but not limited to angioplasty, stent placement, coronary&#xD;
             revascularization), lower extremity bypass procedure, systemic or intracoronary&#xD;
             fibrinolytic therapy within last 5 years&#xD;
&#xD;
          -  Malignancy within the last 5 years (except resected basal cell carcinoma)&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 42 kg/m2&#xD;
&#xD;
          -  Current or expected requirement for anticoagulant therapy (except for ≤ 325 mg/day&#xD;
             aspirin and/or Plavix® 75 mg/day)&#xD;
&#xD;
          -  Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment&#xD;
&#xD;
          -  Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6),&#xD;
             ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents,&#xD;
             sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and&#xD;
             phenytoin&#xD;
&#xD;
          -  Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat&#xD;
             acute flares are permitted)&#xD;
&#xD;
          -  Current or expected treatment with systemic corticosteroids (except topical,&#xD;
             ophthalmic, intra-articular, or inhaled at a dose &lt; 1600 μg/day) other than to treat&#xD;
             acute flares&#xD;
&#xD;
          -  Known hypersensitivity to colchicine&#xD;
&#xD;
          -  Treatment with any other investigational therapy within the 30 days prior to the&#xD;
             Screening Visit, or patients who received at least one dose of blinded study drug&#xD;
             while enrolled in any previous MBX-102 trial&#xD;
&#xD;
          -  Any other condition that compromises the ability of the patient to provide informed&#xD;
             consent or to comply with the objectives and procedures of this protocol, as judged by&#xD;
             the investigator and/or medical monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <disposition_first_submitted>February 19, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 9, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2015</disposition_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

